002294 信立泰
已收盘 04-13 15:00:00
资讯
新帖
简况
新股消息 | 信立泰(002294.SZ)拟港股IPO 证监会要求说明募集资金境内外用途占比
智通财经网 · 04-03
新股消息 | 信立泰(002294.SZ)拟港股IPO 证监会要求说明募集资金境内外用途占比
信立泰（002294）披露SAL0132 I期临床关键数据，4月3日股价下跌2.78%
证券之星 · 04-03
信立泰（002294）披露SAL0132 I期临床关键数据，4月3日股价下跌2.78%
异动快报：信立泰（002294）3月27日13点30分触及涨停板
证券之星 · 03-27
异动快报：信立泰（002294）3月27日13点30分触及涨停板
信立泰(002294.SZ)：自研创新药物SAL0145注射液获批开展MASH适应症临床试验
智通财经 · 03-24
信立泰(002294.SZ)：自研创新药物SAL0145注射液获批开展MASH适应症临床试验
信立泰公布国际专利申请：“用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途”
证券之星 · 03-21
信立泰公布国际专利申请：“用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途”
信立泰最新公告：获得STC007在中国市场瘙痒适应症独家许可权益
证券之星 · 03-20
信立泰最新公告：获得STC007在中国市场瘙痒适应症独家许可权益
3月17日信立泰涨5.84%，中欧医疗健康混合A基金重仓该股
中金财经 · 03-17
3月17日信立泰涨5.84%，中欧医疗健康混合A基金重仓该股
信立泰（002294）披露变更部分募集资金用途用于高血压创新药临床研究公告，3月16日股价上涨5.65%
证券之星 · 03-16
信立泰（002294）披露变更部分募集资金用途用于高血压创新药临床研究公告，3月16日股价上涨5.65%
国金证券：首次覆盖信立泰给予买入评级，目标价70.36元
证券之星 · 03-12
国金证券：首次覆盖信立泰给予买入评级，目标价70.36元
创新药概念震荡反弹 信立泰涨停
每日经济新闻 · 03-10
创新药概念震荡反弹 信立泰涨停
异动快报：信立泰（002294）3月10日11点14分触及涨停板
证券之星 · 03-10
异动快报：信立泰（002294）3月10日11点14分触及涨停板
新股消息 | 远信储能、嘉因生物等拟香港IPO获中国证监会接收材料
智通财经 · 03-06
新股消息 | 远信储能、嘉因生物等拟香港IPO获中国证监会接收材料
3月3日信立泰发布公告，股东减持47.45万股
证券之星 · 03-03
3月3日信立泰发布公告，股东减持47.45万股
信立泰递表港交所 拟于港交所主板上市
中国上市公司网 · 02-24
信立泰递表港交所 拟于港交所主板上市
信立泰递表港交所： 心肾代谢龙头抢滩“A+H”赛道
21世纪经济报道 · 02-14
信立泰递表港交所： 心肾代谢龙头抢滩“A+H”赛道
信立泰药业正式提交港交所上市申请
美股速递 · 02-13
信立泰药业正式提交港交所上市申请
新股消息 | 信立泰(002294.SZ)递表港交所
智通财经 · 02-12
新股消息 | 信立泰(002294.SZ)递表港交所
2月10日信立泰发生1笔大宗交易 成交金额411.55万元
证券之星 · 02-10
2月10日信立泰发生1笔大宗交易 成交金额411.55万元
信立泰（002294）披露控股股东部分股份解除质押公告，2月4日股价上涨4.27%
证券之星 · 02-04
信立泰（002294）披露控股股东部分股份解除质押公告，2月4日股价上涨4.27%
信立泰公布国际专利申请：“一种取代的血管紧张肽和内皮肽受体拮抗剂及其应用”
证券之星 · 01-31
信立泰公布国际专利申请：“一种取代的血管紧张肽和内皮肽受体拮抗剂及其应用”
加载更多
公司概况
公司名称：
深圳信立泰药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-09-10
主营业务：
深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物。
发行价格：
41.98
{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":62.39,"timestamp":1776063828000,"preClose":62.92,"halted":0,"volume":7590241,"delay":0,"changeRate":-0.0084,"floatShares":1115000000,"shares":1115000000,"eps":0.6033,"marketStatus":"已收盘","change":-0.53,"latestTime":"04-13 15:00:00","open":62.58,"high":63.27,"low":61.61,"amount":475000000,"amplitude":0.0264,"askPrice":62.39,"askSize":12,"bidPrice":62.38,"bidSize":347,"shortable":0,"etf":0,"ttmEps":0.6033,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776130200000},"marketStatusCode":5,"adr":0,"adjPreClose":62.92,"symbolType":"stock","openAndCloseTimeList":[[1776043800000,1776051000000],[1776056400000,1776063600000]],"highLimit":69.21,"lowLimit":56.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"isCdr":false,"pbRate":8,"roa":"--","peRate":103.414553,"roe":"6.67%","epsLYR":0.54,"committee":0.648069,"marketValue":69553000000,"turnoverRate":0.0068,"status":1,"floatMarketCap":69538000000},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2624654971","title":"新股消息 | 信立泰(002294.SZ)拟港股IPO 证监会要求说明募集资金境内外用途占比","url":"https://stock-news.laohu8.com/highlight/detail?id=2624654971","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624654971?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:53","pubTimestamp":1775213634,"startTime":"0","endTime":"0","summary":"证监会要求信立泰补充说明募集资金境内外用途占比，是否计划调回境内及调回境内的具体比例，是否涉及投向境外投资项目，是否已履行必要的主管部门审批、核准、备案等程序。同时，证监会要求信立泰按照《监管规则适用指引——境外发行上市类第2号》要求，说明有限责任公司时期设立及股本股东变化情况。截至最后实际可行日期，根据弗若斯特沙利文的资料，该公司拥有按规模计国内企业中第二大的心肾代谢综合征创新药管线。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","BK0196","SPCK","BK0028","BK0183","SPCX","VXUS","BK0239","002294","BK0188","BK4588","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624045656","title":"信立泰（002294）披露SAL0132 I期临床关键数据，4月3日股价下跌2.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624045656","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624045656?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:22","pubTimestamp":1775208176,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，信立泰报收于66.4元，较前一交易日下跌2.78%，最新总市值为740.24亿元。该股当日开盘66.96元，最高68.05元，最低66.0元，成交额达6.9亿元，换手率为0.93%。近日，深圳信立泰药业股份有限公司披露关于SAL0132研发进展的公告。公告显示，其与成都国为合作开发的siRNA创新药SAL0132在2026年美国心脏病学会科学年会上发布了I期临床研究关键数据。SAL0132为靶向肝脏AGT的GalNAc偶联siRNA药物，目前正开展II期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","002294","BK0187","BK0183","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622557817","title":"异动快报：信立泰（002294）3月27日13点30分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2622557817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622557817?lang=zh_cn&edition=full","pubTime":"2026-03-27 13:35","pubTimestamp":1774589728,"startTime":"0","endTime":"0","summary":"证券之星3月27日盘中消息，13点30分信立泰触及涨停板。其所属行业化学制药目前上涨。领涨股为舒泰神。该股为减肥药，创新药，基因编辑概念热股，当日减肥药概念上涨4.75%，创新药概念上涨4.52%，基因编辑概念上涨4.36%。3月26日的资金流向数据方面，主力资金净流出2514.12万元，占总成交额7.99%，游资资金净流入163.03万元，占总成交额0.52%，散户资金净流入2351.09万元，占总成交额7.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700024712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","BK0187","002294","BK0183","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621057186","title":"信立泰(002294.SZ)：自研创新药物SAL0145注射液获批开展MASH适应症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2621057186","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621057186?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:45","pubTimestamp":1774341908,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新药物SAL0145注射液(项目代码：SAL0145)开展MASH适应症的临床试验。SAL0145是公司研发的具有自主知识产权的siRNA药物。临床前研究显示，其具有治疗MASH的潜力。若能研发成功并获批上市，将有望为更多患者提供新的用药选择，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0028","BK0188","159992","BK0183","06978","BK0196","BK0239","BK1574","002294","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621752220","title":"信立泰公布国际专利申请：“用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2621752220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621752220?lang=zh_cn&edition=full","pubTime":"2026-03-21 05:54","pubTimestamp":1774043674,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示信立泰（002294）公布了一项国际专利申请，专利名为“用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途”，专利申请号为PCT/CN2025/120921，国际公布日为2026年3月19日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来信立泰已公布的国际专利申请6个，与去年同期持平。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.35亿元，同比增16.31%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032100004161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002294","BK0028","BK0187","BK0239","BK0196","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620733562","title":"信立泰最新公告：获得STC007在中国市场瘙痒适应症独家许可权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2620733562","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620733562?lang=zh_cn&edition=full","pubTime":"2026-03-20 19:51","pubTimestamp":1774007481,"startTime":"0","endTime":"0","summary":"信立泰公告称，公司与成都诺和晟泰生物科技有限公司签署协议，获得STC007原料药及制剂在中国市场所有瘙痒适应症的独家许可权益，涵盖研发、注册、生产及商业化等。首付款及研发里程碑款合计最高不超过1.25亿元，销售里程碑款累计最高不超过7.25亿元，总金额合计不超过8.5亿元。STC007为外周κ阿片受体激动剂，目前正开展慢性肾脏病相关中至重度瘙痒适应症II期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000037389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0028","BK0188","BK0187","BK0196","BK0183","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620442542","title":"3月17日信立泰涨5.84%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620442542","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620442542?lang=zh_cn&edition=full","pubTime":"2026-03-17 16:25","pubTimestamp":1773735915,"startTime":"0","endTime":"0","summary":"证券之星消息，3月17日信立泰涨5.84%创60日新高，收盘报58.58元，换手率1.53%，成交量17.04万手，成交额9.8亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共51家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为138.43亿元，最新净值1.7241，较上一交易日上涨0.67%，近一年上涨7.71%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/17/20260317439899.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/17/20260317439899.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260317/32074670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0187","LABU","BK0196","XLV","002294","BK0028","BK0239","BK4581","XBI","BK0183","BK0188","159760","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619245504","title":"信立泰（002294）披露变更部分募集资金用途用于高血压创新药临床研究公告，3月16日股价上涨5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619245504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619245504?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:12","pubTimestamp":1773652338,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，信立泰报收于55.35元，较前一交易日上涨5.65%，最新总市值为617.05亿元。近日，深圳信立泰药业股份有限公司发布《关于签订募集资金三方监管协议的公告》。公告显示，公司因变更部分募集资金用途，将原项目“S086沙库巴曲阿利沙坦钙中国II/III期临床研究及上市注册项目”中的30,100万元募集资金用于新项目“部分高血压创新药II/III期临床研究及上市注册项目”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600023232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0028","BK0183","06978","BK1574","BK0187","159992","BK0188","BK1161","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618195180","title":"国金证券：首次覆盖信立泰给予买入评级，目标价70.36元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618195180","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618195180?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:34","pubTimestamp":1773308044,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,唐玉青近期对信立泰进行研究并发布了研究报告《深耕心肾代谢综合征，心衰新药JK07潜力巨大》，首次覆盖信立泰给予买入评级，目标价70.36元。2月13日，公司已正式提交H股上市申请。基于DCF估值模型，计算合理市值为784亿元，对应合理目标价为70.36元。首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200030941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618003836","title":"创新药概念震荡反弹 信立泰涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2618003836","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618003836?lang=zh_cn&edition=full","pubTime":"2026-03-10 11:16","pubTimestamp":1773112560,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月10日，创新药概念盘中震荡反弹，信立泰涨停，海特生物、维康药业（维权）涨超10%，苑东生物、百利天恒、荣昌生物、海思科、科伦药业涨幅靠前。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-10/doc-inhqnmhs6364450.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-10/doc-inhqnmhs6364450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","BK1574","BK0183","002294","BK0187","BK0196","BK1161","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618074536","title":"异动快报：信立泰（002294）3月10日11点14分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2618074536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618074536?lang=zh_cn&edition=full","pubTime":"2026-03-10 11:15","pubTimestamp":1773112521,"startTime":"0","endTime":"0","summary":"证券之星3月10日盘中消息，11点14分信立泰触及涨停板。其所属行业化学制药目前上涨。领涨股为信立泰。该股为基因编辑，创新药，医疗器械概念热股，当日基因编辑概念上涨1.82%，创新药概念上涨1.82%，医疗器械概念上涨1.63%。3月9日的资金流向数据方面，主力资金净流入2753.88万元，占总成交额7.64%，游资资金净流入907.21万元，占总成交额2.52%，散户资金净流出3661.09万元，占总成交额10.15%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000013538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002294","BK0028","BK0187","BK0239","BK0196","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617682342","title":"新股消息 | 远信储能、嘉因生物等拟香港IPO获中国证监会接收材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2617682342","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617682342?lang=zh_cn&edition=full","pubTime":"2026-03-06 19:23","pubTimestamp":1772796207,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月6日，中国证监会发布《境内企业境外发行证券和上市备案情况表(首次公开发行及全流通)(截至2026年3月6日)》。其中，远信储能、嘉因生物、袁记食品、信立泰(002294.SZ)、星源材质(300568.SZ)、康诺生物、星辰天合和酷芯微电子拟香港IPO在中国证监会上市备案状态为\"已接收\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0028","BK0196","002294","BK0155","BK0187","BK0201","BK0229","300568","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616474349","title":"3月3日信立泰发布公告，股东减持47.45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616474349","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616474349?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:01","pubTimestamp":1772535696,"startTime":"0","endTime":"0","summary":"证券之星消息，3月3日信立泰发布公告《信立泰:关于股东减持计划期限届满暨实施情况的公告》，其股东深圳市润复投资发展有限公司于2025年12月4日至2025年12月10日间合计减持47.45万股，占公司目前总股本的0.0426%，变动期间该股股价下跌1.17%，截止12月10日收盘报59.08元。股东增减持详情见下表：根据信立泰2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300037098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0239","BK0196","BK0028","BK0183","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613762715","title":"信立泰递表港交所 拟于港交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2613762715","media":"中国上市公司网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613762715?lang=zh_cn&edition=full","pubTime":"2026-02-24 14:37","pubTimestamp":1771915020,"startTime":"0","endTime":"0","summary":"中国上市公司网讯 2月12日，港交所官网披露了深圳信立泰药业股份有限公司(以下简称“信立泰”)在港交所提交的上市申请，公司上市材料被正式受理，联席保荐人为高盛、花旗和中信证券。公开数 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260224/c674862211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["002294","BK0239","BK0187","BK0028","BK0183","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611119412","title":"信立泰递表港交所： 心肾代谢龙头抢滩“A+H”赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2611119412","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611119412?lang=zh_cn&edition=full","pubTime":"2026-02-14 08:39","pubTimestamp":1771029540,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者 唐唯珂 报道国内心血管领域龙头信立泰，港股上市进程正式步入实质性阶段。2月13日，公司发布公告确认，已于前一日（2月12日）正式向香港联合交易所递交H股发行上市申请 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260214/c674815105.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260214/c674815105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0187","BK0183","002294","BK0196","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160850239","title":"信立泰药业正式提交港交所上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1160850239","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160850239?lang=zh_cn&edition=full","pubTime":"2026-02-13 07:55","pubTimestamp":1770940511,"startTime":"0","endTime":"0","summary":"深圳信立泰药业股份有限公司近日宣布，已正式向香港联合交易所递交上市申请，迈出国际化资本战略的关键一步。此举标志着公司有望通过香港资本市场拓宽融资渠道，进一步提升全球医药市场的品牌影响力与竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0187","BK0183","BK0028","BK0188","002294","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610213849","title":"新股消息 | 信立泰(002294.SZ)递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2610213849","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610213849?lang=zh_cn&edition=full","pubTime":"2026-02-12 21:15","pubTimestamp":1770902148,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所2月12日披露，深圳信立泰药业股份有限公司(002294.SZ)向港交所主板递交上市申请，联席保荐人为高盛、花旗、中信证券。据招股书，信立泰是中国心血管- 肾脏 - 代谢(心肾代谢综合征)疾病治疗领域的先行者。根据弗若斯特沙利文的资料，2024年信立泰是按收入规模计中国心血管创新药领域第二大的制药企业。截至最后实际可行日期，根据弗若斯特沙利文的资料，信立泰拥有按规模计国内企业中第二大的心肾代谢综合征创新药管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","HEXmain","002294","BK0183","BK0239","BK0187","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610864892","title":"2月10日信立泰发生1笔大宗交易 成交金额411.55万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610864892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610864892?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:21","pubTimestamp":1770715267,"startTime":"0","endTime":"0","summary":"证券之星消息，2月10日信立泰发生大宗交易，交易数据如下：大宗交易成交价格52.36元，成交7.86万股，成交金额411.55万元，买方营业部为机构专用，卖方营业部为机构专用。近三个月该股共发生1笔大宗交易，合计成交786.0手。该股近期无解禁股上市。截至2026年2月10日收盘，信立泰(002294)报收于52.36元，上涨6.88%，换手率1.27%，成交量14.15万手，成交额7.32亿元。该股最近90天内共有4家机构给出评级，买入评级4家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000027767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","002294","BK0028","BK0187","BK0183","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608360571","title":"信立泰（002294）披露控股股东部分股份解除质押公告，2月4日股价上涨4.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360571","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608360571?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:10","pubTimestamp":1770214233,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，信立泰报收于48.15元，较前一交易日上涨4.27%，最新总市值为536.78亿元。近日，深圳信立泰药业股份有限公司发布公告，公司控股股东信立泰药业有限公司将其所持公司4,300万股股份解除质押，占其所持股份比例6.77%，占公司总股本比例3.86%。本次解除质押后，香港信立泰累计被质押股份数量为5,400万股，占其持股总数8.50%，占公司总股本4.84%。公司明确该股份质押不涉及业绩补偿义务，不影响公司实际控制权及生产经营。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0196","BK0028","002294","BK0239","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607022701","title":"信立泰公布国际专利申请：“一种取代的血管紧张肽和内皮肽受体拮抗剂及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2607022701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607022701?lang=zh_cn&edition=full","pubTime":"2026-01-31 06:45","pubTimestamp":1769813142,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示信立泰（002294）公布了一项国际专利申请，专利名为“一种取代的血管紧张肽和内皮肽受体拮抗剂及其应用”，专利申请号为PCT/CN2025/110261，国际公布日为2026年1月29日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来信立泰已公布的国际专利申请3个，较去年同期增加了50%。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.35亿元，同比增16.31%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013100005160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0028","BK0196","BK0188","BK0187","BK0183","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776097522252,"stockEarnings":[{"period":"1week","weight":-0.0604},{"period":"1month","weight":0.1909},{"period":"3month","weight":0.1395},{"period":"6month","weight":0.1402},{"period":"1year","weight":0.8957},{"period":"ytd","weight":0.2591}],"compareEarnings":[{"period":"1week","weight":0.028},{"period":"1month","weight":-0.0261},{"period":"3month","weight":-0.0363},{"period":"6month","weight":0.0195},{"period":"1year","weight":0.2317},{"period":"ytd","weight":0.005}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25188人(较上一季度增加4.87%)","perCapita":"44249股","listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","registeredCapital":"111481万元","survey":" 深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物。","listedPrice":41.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}